Maxwell Biosciences

📍 Austin, United States🗓 Founded 2016👥 22 employees💰 Last funded Dec 2022
Biotechnology Research🌐 maxwellbiosciences.com
Website LinkedIn
Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwells first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwells lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwells drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwells “multi-asset, multi-target” anti-infectives drug platform. Maxwells drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.
4
Total investors
0
Early stage
3
Mid stage
1
Late stage
2016
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
2
Tunisia
1
Nigeria
1
Investor activity2020–2022 · investors recorded per year
202022021120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Maxwell Biosciences?
Maxwell Biosciences has 4 investors on record on gritt.io, 3 mid-stage and 1 late-stage investors.
When did Maxwell Biosciences last raise funding?
The most recent investment in Maxwell Biosciences recorded on gritt.io was in December 2022.
When was Maxwell Biosciences founded?
Maxwell Biosciences was founded in 2016.
What industry is Maxwell Biosciences in?
Maxwell Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Maxwell Biosciences based?
Maxwell Biosciences is headquartered in Austin, United States.